- Home
- FENC vs NHS Comparison
FENC vs NHS Comparison
Compare FENC & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- NHS
- Stock Information
- Founded
- FENC 1996
- NHS 2003
- Country
- FENC United States
- NHS United States
- Employees
- FENC 32
- NHS N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- NHS Trusts Except Educational Religious and Charitable
- Sector
- FENC Health Care
- NHS Finance
- Exchange
- FENC Nasdaq
- NHS Nasdaq
- Market Cap
- FENC 222.9M
- NHS 221.6M
- IPO Year
- FENC 2001
- NHS N/A
- Fundamental
- Price
- FENC $8.34
- NHS $7.54
- Analyst Decision
- FENC Strong Buy
- NHS
- Analyst Count
- FENC 2
- NHS 0
- Target Price
- FENC $13.00
- NHS N/A
- AVG Volume (30 Days)
- FENC 83.2K
- NHS 111.8K
- Earning Date
- FENC 08-12-2025
- NHS 01-01-0001
- Dividend Yield
- FENC N/A
- NHS 13.44%
- EPS Growth
- FENC N/A
- NHS N/A
- EPS
- FENC N/A
- NHS N/A
- Revenue
- FENC $30,912,000.00
- NHS N/A
- Revenue This Year
- FENC $0.85
- NHS N/A
- Revenue Next Year
- FENC $55.16
- NHS N/A
- P/E Ratio
- FENC N/A
- NHS N/A
- Revenue Growth
- FENC N/A
- NHS N/A
- 52 Week Low
- FENC $3.96
- NHS $6.95
- 52 Week High
- FENC $8.72
- NHS $9.17
- Technical
- Relative Strength Index (RSI)
- FENC 58.31
- NHS 44.95
- Support Level
- FENC $7.53
- NHS $7.37
- Resistance Level
- FENC $8.68
- NHS $7.51
- Average True Range (ATR)
- FENC 0.49
- NHS 0.07
- MACD
- FENC -0.04
- NHS -0.02
- Stochastic Oscillator
- FENC 63.18
- NHS 26.47
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund is closed-end management investment company. It seeks to achieve its investment objective by investing, under normal market conditions, a majority of its total assets in high yield debt securities of U.S. and foreign issuers.